Navigation Links
Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Date:6/16/2013

study. 70 patients with relapsed/refractory DLBCL with a median of three prior therapies were enrolled, all of whom underwent gene expression profiling to determine which DLBCL subtype they had. All patients received ibrutinib 560 mg orally, once a day, until disease progression or no longer tolerated by the patient. The primary objective of the study was to assess ORR categorized by subtype. Secondary objectives were to assess the safety and tolerability of ibrutinib in people with DLBCL.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development with partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.  

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Hill-Rom Reports Fiscal Second Quarter Adjusted Earnings Per Share In Line With Expectations; Provides Third Quarter And Updated Full-Year Financial Outlook
2. Updated HHS Mandate Continues Attack on Religious Freedom
3. Hoggan Scientific Unveils Updated ergoFET Force Gauge for Improved Force Evaluation
4. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
5. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
6. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. New PrEP Trial Results Among Injecting Drug Users Underscore That PrEP Works When Taken Consistently
9. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
10. Lakeland Industries to Report Fiscal First Quarter Financial Results and Conduct Conference Call
11. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015   Alpha Imaging LLC , ... Cleveland announced today that they have been awarded ... X-ray imaging systems in Michigan.   The new territory supplements Alpha Imaging,s ... states including Ohio , Indiana ... Maryland , West Virginia , ...
(Date:9/1/2015)... Taiwan,s GNT Biotech ... Taipei on  August 25 th ... a targeted drug delivery technology that uses nano-scale gold ... part of a joint press conference held by its ... showcasing GNT,s latest edible gold-based food and beverage partners, ...
(Date:9/1/2015)...   Ivenix Inc. , a medical technology ... on a $42M round of equity financing led ... CICA, Inc., Easterly Capital, Fidelity Biosciences, and SCP ... financing will support the company,s efforts to enter ... acted as the exclusive placement agent for the ...
Breaking Medicine Technology:Alpha Imaging Expands Shimadzu Territory 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... N.J., Nov. 5 Medarex, Inc.,(Nasdaq: MEDX ... milestone payment of,an undisclosed amount from its licensing ... Phase 2 trial of CNTO 95, a fully ... in tumor-induced,angiogenesis. The CNTO 95 human antibody was ...
... Largest Study of Its Kind, PASADENA, Calif., Nov. 4 ... of 37.2 percent -- and as much as 50,percent -- ... Kaiser,Permanente Southern California. The study was published online on November,3 ... journal., The largest study of its kind, the five-year ...
Cached Medicine Technology:Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors 2Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds 2Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds 3Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds 4
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... Celebrity ... Academy will present “The Beauty Behind the Fashion” on Thursday, Oct. 1, at ... (FWSD), will shine the spotlight on the collaboration between fashion and professional hair, makeup ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... prevent different malignancies. Some options for cancer treatment are available belonging to ... distinctive approach is necessary for effective treatment. Several molecules have been discovered ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur Marcella Ellis, ... strongly maintaining her firm’s success in the hair care and distribution industry through ... tour, Ellis will be providing “Look and learn” live demonstrations, as well as ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... analysis of pet vital signs and activity, today announced its integration with leading ... most popular and widely-adopted veterinary hospital Practice Management Software packages in the US. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Zecurion, a leading developer of data ... new version of endpoint DLP developed specifically for Mac OS. , In June 2015, ... 100 IT and information security professionals had participated. The beta test done by the ...
Breaking Medicine News(10 mins):Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Zecurion Announces Endpoint Security for Mac 2
... , ... ... ... ...
... The CREST trial that compared traditional surgery with less-invasive ... neck is being called "seminal and robust." The ... the safety and efficacy of both procedures are roughly ... Canada, is one of the largest randomized stroke prevention ...
... findings could have implications for autism, stroke and other ... Scientists studying the anatomy of children,s brains during reading ... results in a growth of white matter tracts in ... of improvement in sounding out words. , "This ...
... ... ... ... ...
... ... ... ... ...
... ... ... , ... , , ...
Cached Medicine News:Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 2Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 3Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 4Health News:Stents as good as surgery for clogged carotid arteries 2Health News:Reading Remediation Seems to Rewire the Brain 2Health News:Reading Remediation Seems to Rewire the Brain 3Health News:Hope Phones, IntraHealth and FrontlineSMS:Medic Collaborate on Phone Donation Campaign to Support Health Workers in Africa 2Health News:Hope Phones, IntraHealth and FrontlineSMS:Medic Collaborate on Phone Donation Campaign to Support Health Workers in Africa 3Health News:Hope Phones, IntraHealth and FrontlineSMS:Medic Collaborate on Phone Donation Campaign to Support Health Workers in Africa 4Health News:Hope Phones, IntraHealth and FrontlineSMS:Medic Collaborate on Phone Donation Campaign to Support Health Workers in Africa 5Health News:Senate Inaction On Medicare Hurts Seniors, Military and Boomers 2Health News:Senate Inaction On Medicare Hurts Seniors, Military and Boomers 3Health News:Senate Inaction On Medicare Hurts Seniors, Military and Boomers 4Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 2Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 3Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: